Table 21.

GLP-1 RAs: clinical impact and benefits in cholelithiasis

GLP-1 RAs included in the study	Study details	Aim	Highlights
Exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide and semaglutide [183]	Systematic review and meta-analysis of randomised controlled trials [GLP-1 RA (n = 33,167), comparator arms (n = 26,683)]. Duration 41.7 weeks	To evaluate the effect of GLP-1 RA treatment on the incidence of pancreatitis, pancreatic cancer and cholelithiasis in patients with T2DM	Significant increase in cholelithiasis with GLP-1 RAs (OR 1.30 [95% CI 1.01–1.68], P = 0.041). No significant difference in incidence of pancreatitis and pancreatic cancer in both the arms

GLP-1 RA glucagon-like peptide-1 receptor agonist, OR odds ratio, T2DM type 2 diabetes mellitus